Vita Hydrokultur opens £1.5m Series A to scale plant-grown skincare ingredients

Vita Hydrokultur Group Ltd has opened a £1.5m Series A round to expand its plant-based biomanufacturing platform for beauty and wellness ingredients. The London company says the funding will help it validate proteins, commission a Swedish production site and move closer to commercial scale.

Why it matters: - Vita Hydrokultur is targeting a beauty and wellness supply chain that wants higher-performing ingredients with stronger sustainability, traceability and manufacturing resilience. - The global cosmeceutical market is valued at $65.7bn and is projected to reach $152.58bn by 2034. - The company is positioning plant-based biomanufacturing as an alternative to animal, microbial and resource-intensive production methods.

What happened: - Vita Hydrokultur Group Ltd opened a £1.5m Series A funding round on July 27, 2026. - The round is designed to accelerate commercial scale-up and bring plant-expressed ingredients to the global beauty and wellness industry. - Abell Limited is advising on the raise and has supported investment readiness and fundraising strategy. - The company is based in London, with commercial plans tied to Norwich and Sweden.

The details: - Vita Hydrokultur develops and manufactures plant-derived bioactive proteins and botanical active ingredients. - The platform uses Nicotiana benthamiana as a temporary bio-manufacturing unit. - The process instructs the plant to express specific proteins during growth, rather than permanently changing the plant genome. - Harvested molecules are purified with supercritical CO2 extraction to pharmaceutical-grade quality. - The platform is designed to deliver batch-to-batch consistency, animal-free production, full traceability and a non-GMO process. - The company’s R&D facility is planned for Norwich Research Park. - The Norwich site will validate protein expression and optimization protocols as a miniaturized commercial factory. - The planned commercial production facility is in Sweden. - Sweden’s renewable hydroelectric power and faster municipal planning decisions are part of the company’s site rationale. - Vita Hydrokultur has outline approval from the Swedish Gene Technology Advisory Board and is moving toward full commercial operations. - The company says its platform can turn £9 of input into £244 of cosmetic ingredients. - Phase 1 metrics include £638,000 revenue per tower, 88% gross margin and an average selling price of £150/mg. - Vita Hydrokultur projects EBITDA-positive operations in 2029 and £4.8m EBITDA by 2030. - The company forecasts revenue growth from about £60,000 in 2026 to £8.58m. - The long-term plan calls for more than 40 growth towers by year seven. - The current pre-money valuation is £8.8m. - The company is targeting a £96m valuation within five years. - Funding proceeds will go to R&D and protein validation, commissioning the commercial facility, deploying initial growth towers and expanding commercial partnerships with tier-1 ingredient suppliers and formulation labs.

Between the lines: - The raise is as much about proving industrial scale as it is about raising capital. - Vita Hydrokultur is betting that beauty brands will pay for ingredients that combine performance with sustainability and supply-chain resilience. - The company’s cited economics aim to show that high-value bioactive proteins can outperform conventional agricultural products on value density. - Leadership credentials matter here: the team is leaning on experience from vertical farming and controlled-environment agriculture to de-risk execution.

What's next: - Vita Hydrokultur will use the funding round to finish R&D validation and move the Sweden facility closer to commercial production. - The company expects to deploy initial growth towers and deepen partnerships with ingredient suppliers and formulation labs. - Revenue expansion and tower rollout are part of the path toward the company’s five-year valuation target.

The bottom line: - Vita Hydrokultur is trying to turn plant-based molecular farming into a scalable ingredient business for beauty and wellness, with the Series A meant to bridge lab validation and commercial production.